MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Other Events

ME Staff 8-k
-
0

MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Other Events
Item 8.01 Other Events.

On May 26, 2017, the Data and Safety Monitoring Committee (the “DSMC”) for clinical studies of Madrigal Pharmaceuticals, Inc.’s (the “Company”) MGL-3196, for the treatment of non-alcoholic steatohepatitis, held a pre-scheduled meeting to review data from the Company’s Phase 2 clinical NASH trial. The results of the meeting were communicated to Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President, Research & Development, of the “Company”. The DSMC recognized the Company for progress on the clinical trial and recommended that the Company continue the clinical trial with no changes to the protocol. The Company is encouraged by the DSMC’s response and intends to proceed with the clinical trial in accordance with the DSMC’s recommendation. The Company expects to have top-line results for the primary endpoint of the study, the reduction of liver fat, assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at 12 weeks, by year-end 2017.


About MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) Recent Trading Information

MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) closed its last trading session up +0.11 at 15.22 with 6,237 shares trading hands.